
Kiwi Biosciences
Kiwi Biosciences is a YC Summer 2021 (S21) company. Based in Boston, MA, USA. Team of 10.
About Kiwi Biosciences
Summary
Kiwi Biosciences develops novel enzymes that break down FODMAP compounds in food before they can trigger digestive symptoms, targeting people with IBS and other FODMAP sensitivities. Its product, FODZYME, is added directly to meals, replacing the need to follow a strict low-FODMAP elimination diet. The company sells direct-to-consumer and also markets to clinicians.
Business model
Per-unit product purchases, HSA/FSA eligible, sold direct-to-consumer
Go-to-market
IBS sufferers and FODMAP-sensitive individuals buy FODZYME directly online; a parallel clinician-facing channel targets dietitians and gastroenterologists who recommend it to patients.
From the Y Combinator listing
Patent-pending enzymes to break down common dietary triggers
Kiwi Biosciences can help 18M Americans suffering from Irritable Bowel Syndrome (IBS) enjoy a normal meal without running to the bathroom two hours later. We develop novel, patent-pending enzymes that break down common digestive triggers in food.
Facts
- Healthcare / Healthcare -> Consumer Health and Wellness
- Boston, MA, USA
- 10
- Active
- Early
Founders (2)
- Anjie Liu
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works